Antares Pharma Provides Update Regarding the Cowen and Company 38th Annual Healthcare Conference

World News: . []

EWING, N.J., March 13, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the Company) today announced that due to the blizzard conditions and lack of travel options present in the greater Boston area, the Company will be unable to attend the Cowen and Company 38 Annual Healthcare Conference on Wednesday, March 14, 2018.

This morning, Antares executives provided a Company update and reviewed fourth quarter and full year 2017 financial results via webcast and conference call.  A copy of the press release can be found on the Antares Pharma website at , under the “For Investors” section.  A telephone replay of today’s conference call is available until 11:30 a.m. ET on Thursday, April 12, 2018, and can be accessed by dialing 1-888-203-1112 (US) or 1-719-457-0820 (International) and entering passcode 6501930.  Callers can also access the slide presentation on the “For Investors” section of the Company’s website under “Presentations.”

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company’s product, OTREXUP (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company’s product Sumatriptan Injection USP, is approved in the U.S. for the acute treatment of migraine and cluster headache and is distributed by Teva Pharmaceutical Industries, Ltd. (Teva). Antares Pharma is also developing an investigational new drug, XYOSTED™, for the treatment of testosterone deficiency (hypogonadism). The Company filed a New Drug Application for XYOSTED™ and received a Complete Response Letter.  The Company's technology platforms include VIBEX disposable auto injectors and disposable multi-use pen injectors. Antares Pharma has license, development and supply agreements with Teva that include VIBEX epinephrine, exenatide multi-dose pen, and teriparatide multi-dose pen. The Company also provides AMAG Pharmaceuticals with a subcutaneous QuickShot auto injector for administering Makena.  For more information, visit .

Jack HowarthVice President, Corporate

More news and information about Antares Pharma, Inc.

Published By:

Globe Newswire: 21:45 GMT Tuesday 13th March 2018

Published: .

Search for other references to "antares" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers